HALO 8-K 2026-09-22
HALOZYME THERAPEUTICS, INC. (HALO) 8-K dated 2026-09-22 — accession 0001193125-26-398015.
HALOZYME THERAPEUTICS, INC. (HALO) is a biotechnology company listed on US.
HALOZYME THERAPEUTICS, INC. filed a 8-K on 2026-09-22. Accession 0001193125-26-398015.
This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Unregistered share sale (Item 3.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B and trailing P/E 26.8.
Not investment advice. The HALO SEC hub lists recent forms. The stock page is the research view.